WuXi increases GMP plasmid DNA services

By The Science Advisory Board staff writers

November 12, 2020 -- WuXi Advanced Therapies has expanded its cell and gene therapy platforms with capabilities to provide high-quality and cost-effective good manufacturing practice (GMP) plasmids.

With these enhanced capabilities, the company can assist customers in overcoming current plasmid DNA supply constraints and expediting research and development and manufacturing processes of cell and gene therapy applications. WuXi is able to leverage its experience in testing of raw materials and biotherapeutics as well as in-house quality control and analytical services to ensure the safety of well-characterized and fully released plasmids.

WuXi Biologics leases U.S. manufacturing facility
Hong Kong-based WuXi Biologics has signed a 10-year lease for a clinical manufacturing facility in Cranbury, NJ, making it the company's third site in...
WuXi to build manufacturing facility in U.S.
WuXi Biologics announced it has signed a deal with Worcester Business Development to build a clinical and commercial manufacturing facility in Worcester,...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter